TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes
Brief Summary: This trial was conducted in Europe, Middle East, North America and South America.

The aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart (NovoRapid®) versus human insulin (Actrapid®) in pregnancy.


Options:
A: Intervention Type: DRUG; Name: cinnamon; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cinnamon or placebo 500 mg capsule twice daily | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinnamon or placebo 500 mg capsule twice daily | Intervention Type: DRUG; Name: Cinnamon or placebo 500 mg capsule twice daily; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: Coccinia Cordifolia (herbal extract); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Double Blinded, Randomized, Placebo Controlled Trial of Proton Pump Inhibitor for the Prevention of Recurrent Ulcer Bleeding in Patients Receiving a COX-2 Inhibitor
Brief Summary: The purpose of this study is to compare the effect of Esomeparzole with Placebo in the Prevention of Recurrent Ulcer Bleeding in Patients Receiving a COX-2 Inhibitor


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac + Omeprazole | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Diclofenac + Omeprazole; Assigned to Arm(s): B
B: Intervention Type: DRUG; Name: celecoxib, esomeprazole; Assigned to Arm(s): N/A
C: Arm Label: Pelubiprofen 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Pelubiprofen 30 mg | Arm Label: Celebrex 200 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Celebrex 200 mg | Intervention Type: DRUG; Name: Pelubiprofen 30 mg; Assigned to Arm(s): Pelubiprofen 30 mg | Intervention Type: DRUG; Name: Celebrex 200 mg; Assigned to Arm(s): Celebrex 200 mg
D: Arm Label: celecoxib; Type: EXPERIMENTAL; Interventions: Drug: celecoxib | Arm Label: ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: naproxen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naproxen | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): celecoxib | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): ibuprofen | Intervention Type: DRUG; Name: Naproxen; Assigned to Arm(s): naproxen

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.
Brief Summary: The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).


Options:
A: Arm Label: XP13512 600MG; Type: EXPERIMENTAL; Interventions: Drug: XP13512 600MG | Arm Label: XP13512 1200MG; Type: EXPERIMENTAL; Interventions: Drug: XP13512 1200MG | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: XP13512 600MG; Assigned to Arm(s): XP13512 600MG | Intervention Type: DRUG; Name: XP13512 1200MG; Assigned to Arm(s): XP13512 1200MG | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): Placebo
B: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group
C: Arm Label: GEn (XP13512/GSK1838262) 600 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 1200 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 1800 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: GEn (XP13512/GSK1838262) 2400 mg; Type: EXPERIMENTAL; Interventions: Drug: GEn (XP13512/GSK1838262) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GEn (XP13512/GSK1838262); Assigned to Arm(s): GEn (XP13512/GSK1838262) 1200 mg, GEn (XP13512/GSK1838262) 1800 mg, GEn (XP13512/GSK1838262) 2400 mg, GEn (XP13512/GSK1838262) 600 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: XP13512 (GSK1838262); Type: EXPERIMENTAL; Interventions: Drug: XP13512 (GSK1838262) | Intervention Type: DRUG; Name: XP13512 (GSK1838262); Assigned to Arm(s): XP13512 (GSK1838262) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Pilot Manufacturing Lot of HPV 16 Virus-Like Particle (VLP) Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females
Brief Summary: Subjects received HPV 16 L1 VLP vaccine or placebo (1:1 ratio). Endpoints included efficacy, immunogenicity, and safety.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Comparator: HPV 16 L1 Vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: Comparator: HPV 16 L1 Vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2
B: Arm Label: A: HAART naive or no HAART in past 6 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV vaccine for strains -6, -11, -16, and -18 | Arm Label: B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months; Type: ACTIVE_COMPARATOR; Interventions: Biological: HPV vaccine for strains -6, -11, -16, and -18 | Intervention Type: BIOLOGICAL; Name: HPV vaccine for strains -6, -11, -16, and -18; Assigned to Arm(s): A: HAART naive or no HAART in past 6 months, B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months
C: Arm Label: Cervarix/Engerix-B A Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Cervarix/Engerix-B B Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group | Intervention Type: BIOLOGICAL; Name: Engerix-B; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group, Engerix-B Group
D: Arm Label: Cervarix Group; Type: OTHER; Interventions: Procedure: Blood sampling | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SAFE or SORRY? Development and Testing of an Evidence Based Inpatient Safety Program for the Prevention of Common Complications.
Brief Summary: The aim of SAFE or SORRY? is to develop and test an evidence based inpatient safety program for the prevention of three frequently occuring adverse events: pressure ulcers, urinary tract infections and falls.


Options:
A: Arm Label: Group A, Sunlight; Type: ACTIVE_COMPARATOR; Interventions: Other: Sunlight | Arm Label: Group B, sunlight and calcium; Type: ACTIVE_COMPARATOR; Interventions: Other: Sunlight and calcium | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: Other: control | Intervention Type: OTHER; Name: Sunlight; Assigned to Arm(s): Group A, Sunlight | Intervention Type: OTHER; Name: Sunlight and calcium; Assigned to Arm(s): Group B, sunlight and calcium | Intervention Type: OTHER; Name: control; Assigned to Arm(s): Group C
B: Arm Label: Person-centered Care; Type: EXPERIMENTAL; Interventions: Other: Person-centered Care, Other: Optimised Treatment | Arm Label: Optimised Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimised Treatment | Intervention Type: OTHER; Name: Person-centered Care; Assigned to Arm(s): Person-centered Care | Intervention Type: OTHER; Name: Optimised Treatment; Assigned to Arm(s): Optimised Treatment, Person-centered Care
C: Arm Label: RASP; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmaceutical care plan, mostly based on the RASP | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmaceutical care plan, mostly based on the RASP; Assigned to Arm(s): RASP
D: Intervention Type: BEHAVIORAL; Name: safety program; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SAFE or SORRY? Development and Testing of an Evidence Based Inpatient Safety Program for the Prevention of Common Complications.
Brief Summary: The aim of SAFE or SORRY? is to develop and test an evidence based inpatient safety program for the prevention of three frequently occuring adverse events: pressure ulcers, urinary tract infections and falls.


Options:
A: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Educational intervention program; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Multi-Source Feedback: including self-assessment & coaching; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: safety program; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SAFE or SORRY? Development and Testing of an Evidence Based Inpatient Safety Program for the Prevention of Common Complications.
Brief Summary: The aim of SAFE or SORRY? is to develop and test an evidence based inpatient safety program for the prevention of three frequently occuring adverse events: pressure ulcers, urinary tract infections and falls.


Options:
A: Arm Label: Implementation intervention; Type: EXPERIMENTAL; Interventions: Other: Implementation intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation intervention; Assigned to Arm(s): Implementation intervention
B: Intervention Type: BEHAVIORAL; Name: Educational intervention; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: safety program; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Multi-Source Feedback: including self-assessment & coaching; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 Mcg (2 Actuations of 2.5 Mcg) and 10 Mcg (2 Actuations of 5 Mcg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler® as Add-on Therapy in Patients With Severe Persistent Asthma
Brief Summary: The primary objective of this study is to examine efficacy and safety of tiotropium compared to plac ebo as add-on therapy in severe asthmatics according to GINA step 4 classification


Options:
A: Arm Label: tiotropium low dose once daily; Type: EXPERIMENTAL; Interventions: Drug: tiotropium bromide 1.25µg once daily | Arm Label: tiotropium medium dose once daily; Type: EXPERIMENTAL; Interventions: Drug: tiotropium bromide 2.5µg once daily | Arm Label: tiotropium high dose once daily; Type: EXPERIMENTAL; Interventions: Drug: tiotropium bromide high dose once daily | Arm Label: Placebo once daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tiotropium matching Placebo once daily | Intervention Type: DRUG; Name: tiotropium bromide 2.5µg once daily; Assigned to Arm(s): tiotropium medium dose once daily | Intervention Type: DRUG; Name: Tiotropium matching Placebo once daily; Assigned to Arm(s): Placebo once daily | Intervention Type: DRUG; Name: tiotropium bromide high dose once daily; Assigned to Arm(s): tiotropium high dose once daily | Intervention Type: DRUG; Name: tiotropium bromide 1.25µg once daily; Assigned to Arm(s): tiotropium low dose once daily
B: Arm Label: Tiotropium daily dose q.d.; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium 5 µg q.d. | Arm Label: Tiotropium half daily dose b.i.d.; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium 2.5 µg b.i.d | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tiotropium 2.5 µg b.i.d; Assigned to Arm(s): Tiotropium half daily dose b.i.d. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tiotropium 5 µg q.d.; Assigned to Arm(s): Tiotropium daily dose q.d.
C: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol xinafoate; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 Mcg (2 Actuations of 2.5 Mcg) and 10 Mcg (2 Actuations of 5 Mcg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler® as Add-on Therapy in Patients With Severe Persistent Asthma
Brief Summary: The primary objective of this study is to examine efficacy and safety of tiotropium compared to plac ebo as add-on therapy in severe asthmatics according to GINA step 4 classification


Options:
A: Arm Label: Xolair; Type: EXPERIMENTAL; Interventions: Drug: omalizumab (Xolair), Drug: corticosteroids, Drug: long-acting beta-agonists | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: corticosteroids, Drug: long-acting beta-agonists | Intervention Type: DRUG; Name: omalizumab (Xolair); Assigned to Arm(s): Xolair | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: corticosteroids; Assigned to Arm(s): Xolair, placebo | Intervention Type: DRUG; Name: long-acting beta-agonists; Assigned to Arm(s): Xolair, placebo
B: Intervention Type: DRUG; Name: fluticasone propionate/salmeterol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): N/A
C: Arm Label: Omalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen
Brief Summary: To compare the effectiveness (efficacy, safety \& tolerability) of a Single Tablet Regimen of efavirenz/emtricitabine/tenofovir DF to subjects continuing on unmodified HAART as measured by the proportion of patients who maintain viral load (HIV-1 RNA) \<200 copies/mL at Week 48.


Options:
A: Intervention Type: BEHAVIORAL; Name: Semi-structured, open ended interview; Assigned to Arm(s): N/A
B: Arm Label: Reciprocal Diabetes Peer Support program; Type: EXPERIMENTAL; Interventions: Behavioral: Reciprocal Diabetes Peer Support Program, Behavioral: group outpatient counseling visits | Arm Label: Nurse Case Management; Type: OTHER; Interventions: Behavioral: Nurse Case management | Intervention Type: BEHAVIORAL; Name: Reciprocal Diabetes Peer Support Program; Assigned to Arm(s): Reciprocal Diabetes Peer Support program | Intervention Type: BEHAVIORAL; Name: Nurse Case management; Assigned to Arm(s): Nurse Case Management | Intervention Type: BEHAVIORAL; Name: group outpatient counseling visits; Assigned to Arm(s): Reciprocal Diabetes Peer Support program
C: Intervention Type: DRUG; Name: Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF); Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Simvastatin on Clinical, Endocrine, Metabolic and Biochemical Parameters of Women With Polycystic Ovary Syndrome: Prospective, Randomized Trial.
Brief Summary: The purpose of this study is to determine whether statins (simvastatin) improve clinical (excessive hair, skin problems), endocrine (androgens) and metabolic (lipids, markers of systemic inflammation) in women with polycystic ovary syndrome (PCOS).


Options:
A: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
B: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin and Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Simvastatin on Clinical, Endocrine, Metabolic and Biochemical Parameters of Women With Polycystic Ovary Syndrome: Prospective, Randomized Trial.
Brief Summary: The purpose of this study is to determine whether statins (simvastatin) improve clinical (excessive hair, skin problems), endocrine (androgens) and metabolic (lipids, markers of systemic inflammation) in women with polycystic ovary syndrome (PCOS).


Options:
A: Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): N/A
B: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Metformin, Placebo
C: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Metformin plus spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin plus Spironolactone | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Metformin plus Spironolactone; Assigned to Arm(s): Metformin plus spironolactone
D: Arm Label: 3 mg drospirenone and 20 µg ethinyl-estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 mg drospirenone and 20 µg ethinyl-estradiol | Arm Label: 3 mg drospirenone and 30 µg ethinyl-estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 mg drospirenone and 30 µg ethinyl-estradiol | Intervention Type: DRUG; Name: 3 mg drospirenone and 20 µg ethinyl-estradiol; Assigned to Arm(s): 3 mg drospirenone and 20 µg ethinyl-estradiol | Intervention Type: DRUG; Name: 3 mg drospirenone and 30 µg ethinyl-estradiol; Assigned to Arm(s): 3 mg drospirenone and 30 µg ethinyl-estradiol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telephone-Delivered Coping Improvement Intervention for HIV Infected Older Adults
Brief Summary: This study will evaluate the effectiveness of a telephone-delivered coping improvement group intervention in improving quality of life in older adults with HIV.


Options:
A: Arm Label: Mentor Mothers Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer support and mentoring | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer support and mentoring; Assigned to Arm(s): Mentor Mothers Intervention
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone-administered supportive-expressive therapy | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone-administered coping improvement therapy | Intervention Type: BEHAVIORAL; Name: Telephone-administered coping improvement therapy; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Telephone-administered supportive-expressive therapy; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Individual therapy; Assigned to Arm(s): 1
C: Arm Label: Family Function Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Familias Unidas | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Familias Unidas; Assigned to Arm(s): Family Function Intervention
D: Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-AD | Arm Label: ETAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ETAU | Intervention Type: BEHAVIORAL; Name: CBT-AD; Assigned to Arm(s): CBT-AD | Intervention Type: BEHAVIORAL; Name: ETAU; Assigned to Arm(s): ETAU

Answer: B